Yoshikazu Takada

This study shows Galectin-3 binds to integrins αvβ3, αIIbβ3, and α5β1 in a glycan-independent manner and activates them through two distinct sites, with implications for inflammation and thrombosis.

This study shows ivermectin binds to the allosteric site 2 of integrins and inhibits their activation by pro-inflammatory cytokines, similar to anti-inflammatory cytokines.

This study shows FGF2 activates integrin αIIbβ3 via site 2, while FGF1 binds site 2 but inhibits FGF2-induced activation, suggesting FGF1's anti-thrombotic mechanism.

This study shows FGF2 activates αvβ3 integrin via site 2, while FGF1 binds site 2 but suppresses integrin activation, suggesting FGF1's anti-inflammatory action is through blocking site 2.

This study identifies FGF9 as a new ligand for integrin αvβ3 and shows that a mutant defective in integrin binding acts as an antagonist by suppressing FGF9 signaling.